The World Health Organization (WHO) has finalized the influenza vaccine strains for the 2026-27 northern hemisphere season. This critical update follows a comprehensive review of global surveillance data, aiming to combat seasonal influenza which causes hundreds of thousands of respiratory deaths annually.
The recommendation stems from a 4-day consultation with experts from the Global Influenza Surveillance and Response System. This year's update was significantly influenced by the rapid global spread of a new A(H3N2) variant, designated J.2.4.1 or "subclade K," which emerged in August 2025. This variant contributed to an unusually intense influenza season in multiple countries.
Experts also addressed zoonotic influenza viruses, a potential pandemic threat. Since September 2025, 25 human cases have been reported across six countries, primarily linked to animal exposure. No human-to-human transmission has been confirmed. A candidate vaccine virus targeting A(H9N2) is being developed as a precautionary measure.
The recommended vaccine composition for the 2026-27 season includes updated strains for both egg-based and cell- or recombinant-based platforms. These comprise A(H1N1)pdm09-like, A(H3N2)-like, and B/Victoria lineage-like viruses, selected for their close alignment with currently circulating strains.
This annual composition update is vital for clinicians and public health officials, ensuring vaccines provide the most effective protection against emergent influenza strains and helping to reduce hospitalizations and mortality.